Therefore, combining regorafenib with ICIs may be a novel therapeutic strategy to overcome regorafenib resistance, as the combination of ICI and VEGF inhibitors, such as atezo + bev combination therapy, has shown anti-tumor synergistic effects against HCC [205]. The gene discussed is VEGFA; the disease is neoplasm.